These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15095265)

  • 1. TIMP-3 and endocrine therapy of breast cancer: an apoptosis connection emerges.
    Edwards DR
    J Pathol; 2004 Apr; 202(4):391-4. PubMed ID: 15095265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success.
    Span PN; Lindberg RL; Manders P; Tjan-Heijnen VC; Heuvel JJ; Beex LV; Sweep CG
    J Pathol; 2004 Apr; 202(4):395-402. PubMed ID: 15095266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells.
    Kim JR; Kim CH
    Int J Biochem Cell Biol; 2004 Nov; 36(11):2293-306. PubMed ID: 15313474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3.
    Baker AH; George SJ; Zaltsman AB; Murphy G; Newby AC
    Br J Cancer; 1999 Mar; 79(9-10):1347-55. PubMed ID: 10188875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
    Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
    Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue inhibitor of metalloproteinases-1 in breast cancer.
    Würtz SØ; Schrohl AS; Sørensen NM; Lademann U; Christensen IJ; Mouridsen H; Brünner N
    Endocr Relat Cancer; 2005 Jun; 12(2):215-27. PubMed ID: 15947098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
    Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
    Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer.
    Schrohl AS; Meijer-van Gelder ME; Holten-Andersen MN; Christensen IJ; Look MP; Mouridsen HT; Brünner N; Foekens JA
    Clin Cancer Res; 2006 Dec; 12(23):7054-8. PubMed ID: 17114213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer.
    Lee YK; So IS; Lee SC; Lee JH; Lee CW; Kim WM; Park MK; Lee ST; Park DY; Shin DY; Park CU; Kim YS
    J Gene Med; 2005 Feb; 7(2):145-57. PubMed ID: 15546163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy.
    Premkumar VG; Yuvaraj S; Sathish S; Shanthi P; Sachdanandam P
    Vascul Pharmacol; 2008; 48(4-6):191-201. PubMed ID: 18407793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue inhibitor of metalloproteinases-1 stimulates gene expression in MDA-MB-435 human breast cancer cells by means of its ability to inhibit metalloproteinases.
    Porter JF; Sharma S; Wilson DL; Kappil MA; Hart RP; Denhardt DT
    Breast Cancer Res Treat; 2005 Nov; 94(2):185-93. PubMed ID: 16142437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic expression of matrix metalloproteinases (MMP-2, -9 and -14) and the tissue inhibitors of MMPs (TIMP-1, -2 and -3) at the implantation site during tubal pregnancy.
    Bai SX; Wang YL; Qin L; Xiao ZJ; Herva R; Piao YS
    Reproduction; 2005 Jan; 129(1):103-13. PubMed ID: 15615902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue inhibitor of metalloproteinases-3 interacts with angiotensin II type 2 receptor and additively inhibits angiogenesis.
    Kang KH; Park SY; Rho SB; Lee JH
    Cardiovasc Res; 2008 Jul; 79(1):150-60. PubMed ID: 18344519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
    Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
    Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TIMP-1 as a tumor marker in breast cancer--an update.
    Würtz SO; Schrohl AS; Mouridsen H; Brünner N
    Acta Oncol; 2008; 47(4):580-90. PubMed ID: 18465326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase-9 (MMP-9) immunoreactive protein has modest prognostic value in locally advanced breast carcinoma patients treated with an adjuvant antiestrogen therapy.
    Rahko E; Jukkola A; Melkko J; Paavo P; Bloigu R; Talvensaari-Mattila A; Turpeenniemi-Hujanen T
    Anticancer Res; 2004; 24(6):4247-53. PubMed ID: 15736480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; A'Hern R
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1024s-1030s. PubMed ID: 16467120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoexpression and prognostic significance of TIMP-1 and -2 in oral squamous cell carcinoma.
    de Vicente JC; Fresno MF; Villalain L; Vega JA; López Arranz JS
    Oral Oncol; 2005 Jul; 41(6):568-79. PubMed ID: 15925538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.